Sight Sciences, Inc.SGHTEarnings & Financial Report
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
Revenue
$19.9M
Gross Profit
$17.2M
Operating Profit
$-7.9M
Net Profit
$-8.2M
Gross Margin
86.4%
Operating Margin
-39.7%
Net Margin
-41.0%
YoY Growth
-1.2%
EPS
$-0.16
Sight Sciences, Inc. Q3 FY2025 Financial Summary
Sight Sciences, Inc. reported revenue of $19.9M (down 1.2% YoY) for Q3 FY2025, with a net profit of $-8.2M (up 26.2% YoY) (-41.0% margin). Cost of goods sold was $2.7M, operating expenses totaled $25.1M.
Key Financial Metrics
| Total Revenue | $19.9M |
|---|---|
| Net Profit | $-8.2M |
| Gross Margin | 86.4% |
| Operating Margin | -39.7% |
| Report Period | Q3 FY2025 |
Sight Sciences, Inc. Annual Revenue by Year
Sight Sciences, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $77.4M).
| Year | Annual Revenue |
|---|---|
| 2025 | $77.4M |
| 2024 | $79.9M |
| 2023 | $81.1M |
| 2022 | $71.3M |
Sight Sciences, Inc. Quarterly Revenue & Net Profit History
Sight Sciences, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $20.4M | +6.9% | $-4.2M | -20.4% |
| Q3 FY2025 | $19.9M | -1.2% | $-8.2M | -41.0% |
| Q2 FY2025 | $19.6M | -8.5% | $-11.9M | -61.0% |
| Q1 FY2025 | $17.5M | -9.1% | $-14.2M | -80.8% |
| Q4 FY2024 | $19.1M | +1.7% | $-11.8M | -62.1% |
| Q3 FY2024 | $20.2M | +0.7% | $-11.1M | -54.9% |
| Q2 FY2024 | $21.4M | -9.0% | $-12.3M | -57.7% |
| Q1 FY2024 | $19.3M | +2.3% | $-16.3M | -84.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19.3M | $21.4M | $20.2M | $19.1M | $17.5M | $19.6M | $19.9M | $20.4M |
| YoY Growth | 2.3% | -9.0% | 0.7% | 1.7% | -9.1% | -8.5% | -1.2% | 6.9% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $155.6M | $149.7M | $143.6M | $142.8M | $129.7M | $122.0M | $116.3M | $115.3M |
| Liabilities | $46.4M | $48.1M | $48.6M | $55.3M | $52.1M | $52.0M | $52.0M | $51.4M |
| Equity | $109.2M | $101.6M | $95.0M | $87.5M | $77.6M | $70.0M | $64.3M | $63.9M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-9.8M | $-9.5M | $362000 | $-3.5M | $-11.6M | $-7.5M | $-8.7M | $-1.8M |